Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2021
Reporting Period: Quarterly period ended September 30, 2021
This filing serves as a notification that the company issued a press release announcing its financial results for the quarter ended September 30, 2021. The full text of the press release is attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the attached press release (Exhibit 99.1), which is furnished but not included in the text of this 8-K summary.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is contained within the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 4, 2021) for actual financial results.
- Verify specific revenue, net loss, and cash position figures for the quarter ended September 30, 2021.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm liquidity status and cash runway projections provided in the full announcement.